



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this RESPONSE TO NOTICE TO COMPLY and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date indicated below with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Ariel Fletcher

Ariel Fletcher

1/21/2003  
Date of Deposit

Applicant: Joyce, et al. )  
Serial No.: 09/423,035 ) Group Art Unit: 1635  
Filed: January 13, 2000 ) Examiner: K. Lacourciere  
Title: ENZYMATIC DNA MOLECULES ) Our Ref.: TSRI 463.4

#22/K.T.  
2/4  
Sg.  
Amclt  
E

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT  
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO  
ACID SEQUENCE DISCLOSURES (37 CFR §1.821-1.825)**

Assistant Commissioner for Patents  
Box Sequence, P.O. Box 2327  
Arlington, VA 22202

Dear Sir:

In response to the enclosed copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures Under 37 CFR §1.821-1.825 mailed October 22, 2002, enclosed is a substitute Sequence Listing on paper copy, made in accordance with 37 CFR §1.821 - §1.825. Also enclosed is the substitute Sequence Listing in computer readable form, submitted as required by 37 CFR §1.821(e), on which the substitute Sequence Listing is labeled TSRI 463\_4. A Petition for a Two Month Extension of Time and a check in the amount of \$410.00 to cover the cost of that Petition is also enclosed.

Applicants respectfully request entry of the Sequence Listing and computer readable copy thereof.

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(a) through (c) and (e), respectively, are the same and include no new matter.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that making willful false statements and the like is punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Entry of the following amendment is respectfully requested.

Please amend the above-identified application as follows:

In The Specification:    /

At page 15, line 27, please substitute the following paragraph for the previous version:

E1  
Figure 1 illustrates a selective amplification scheme for isolation of DNAs that cleave a target RNA phosphoester. As shown, double-stranded DNA that contains a stretch of 50 random nucleotides (the molecule with "N<sub>50</sub>" (SEQ ID NO 145) indicated above it) is amplified by PCR, employing a 5'-biotinylated DNA primer that is terminated at the 3' end by an adenosine